Kymera Therapeutics, Inc.

KYMR · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
111
SEC Filings

Business Summary

PART I . We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologie...

Next Earnings

Q2 FY2026 — expected 2026-09-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionKYMRdiscussed_in_filing Cybersecurity
topic_mentionKYMRdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-073395EDGAR104K words
2025-02-272024-12-310000950170-25-028355EDGAR—
2024-02-222023-12-310000950170-24-018414EDGAR—
2023-02-232022-12-310000950170-23-003935EDGAR—
2022-02-242021-12-310000950170-22-001860EDGAR—
2021-03-112020-12-310001564590-21-012240EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-042025-09-300001193125-25-263550EDGAR70K words
2025-08-112025-06-300000950170-25-106229EDGAR—
2025-05-092025-03-310000950170-25-067498EDGAR—
2024-10-312024-09-300000950170-24-119249EDGAR—
2024-08-072024-06-300000950170-24-092275EDGAR—
2024-05-022024-03-310000950170-24-051567EDGAR—
2023-11-022023-09-300000950170-23-057743EDGAR—
2023-08-032023-06-300000950170-23-037581EDGAR—
2023-05-042023-03-310000950170-23-017462EDGAR—
2022-11-032022-09-300000950170-22-021543EDGAR—
2022-08-092022-06-300000950170-22-015745EDGAR—
2022-05-032022-03-310000950170-22-006947EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-270001193125-26-129170EDGAR1K words
2026-02-260001193125-26-073561EDGAR—
2026-02-260001193125-26-073386EDGAR—
2026-01-130001193125-26-011104EDGAR—
2025-12-100001193125-25-314422EDGAR—
2025-12-080001193125-25-310670EDGAR—
2025-12-080001193125-25-310572EDGAR—
2025-11-040001193125-25-263540EDGAR—
2025-09-030001193125-25-194481EDGAR—
2025-08-110000950170-25-106227EDGAR—

111 total filings indexed. 83 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001815442
TickerKYMR
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9d604a203c7c74e491dc523addc8ed0930933b32b9f66a7e4e7d21ce7a60b9c4
parent: bce8faedd7708e5e0c0d0c122227785a27924a711505d1b1be0b996132c2a977
content hash: d510ab373239daa25b1c922d5209ff0beca584f581d9d81db4241159d24de511
signed: 2026-04-13T04:45:57.472Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf